Pharmacovigilance - EOF

close

Home » Medicines » Archive by Category "Pharmacovigilance" (Page 4)

EMA starts review of sickle cell anemia drug Oxbryta

Mysimba: EMA advises on the risks of its use with opioid medicines

PRAC meeting highlights 8-11 July 2024

Highlights of the Pharmacovigilance Risk Assessment Committee (PRAC) meeting 10-13 June 2024

Hydroxyprogesterone caproate preparations to be suspended from the EU market

Valproate preparations – PRAC recommends precautionary measures for the treatment of male patients

PRAC recommends measures to minimise the risk of serious side effects from pseudoephedrine-containing medicines

Valproic Acid: EMA review of data on paternal exposure

EMA announcement on the ongoing review of GLP-1 receptor agonists

Key points from the Pharmacovigilance Risk Assessment Committee (PRAC) meeting on 10 – 12 May 2023

fmpkilbepgnelmhp

iso-footer

Data Protection Officer: dpo at eof dot gr

Archive (old website)